Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2039

Annual patent cliff calendar for 2039 — US pharmaceutical patents by expiration date.

Patents
1,782

Quick answer

1,782 indexed pharmaceutical patents have expiration dates in 2039. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 10513494

    Methods, compounds, and compositions for anesthesia

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Dec 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10512693

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Dec 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10512692

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Dec 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10512682

    Norovirus vaccine formulations

    Takeda Vaccines, Inc. · Granted Tue Dec 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10512675

    Adeno-associated virus factor VIII vectors, associated viral particles and therapeutic formulations comprising the same

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue Dec 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10512672

    Methods for the treatment of inflammatory joint disease

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Dec 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10512673

    Use of peptide-based inhibitors of the stat3-IL10 pathway for treating bacterial infection and granulomatous disease

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10512671

    IL-24 to treat inflammatory diseases

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10512649

    Methods and compositions for treatment of zika virus infection

    BioCryst Pharmaceuticals, Inc. · Granted Tue Dec 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10512667

    Compositions and methods for treating conditions related to adrenocortical activity and/or excessive steroid production

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Dec 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10512630

    Compositions and methods for treating cancer

    The Regents of the University of California · Granted Tue Dec 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10512637

    Use of inhibitor of cystine-glutamate transporter

    China Medical University · Granted Tue Dec 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10517894

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10517890

    Triggering RNA interference with RNA-DNA and DNA-RNA nanoparticles

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10517950

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10519467

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10517917

    Compositions and methods for preventing or treating pulmonary hypertension

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10517898

    Compositions and methods related to hematologic recovery

    The Regents of the University of California · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10517874

    sGC stimulators

    Cyclerion Therapeutics, Inc. · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10517860

    Combination of pimavanserin and cytochrome P450 modulators

    ACADIA Pharmaceuticals Inc. · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10517491

    Cardiac phase-resolved non-breath-hold 3-dimensional magnetic resonance angiography

    The Regents of the University of California · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10517853

    Methods for treating epilepsy

    PTC THERAPEUTICS, INC. · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10517924

    High density lipoprotein nanoparticles for inflammation

    Northwestern University · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10517942

    Polypeptide glycopeptide fragments from the V1/V2 and V3 domains of the HIV-1 envelope protein gp 120

    The Regents of the University of California · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10517948

    Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy

    The Board of Regents of the University of Texas System · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10519138

    Modulators of SOCE, compositions, and uses thereof

    UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10517864

    Sustained-release buprenorphine solutions

    Indivior UK Limited · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10517869

    Topical brimonidine tartrate ophthalmic solution

    SENTISS PHARMA PRIVATE LIMITED · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10519230

    Nucleic acids encoding IL-33 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10519153

    Fused imidazo-piperidine JAK inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10518074

    Compositions comprising nanostructures for cell, tissue and artificial organ growth, and methods for making and using same

    The Regents of the University of California · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10517920

    Antibacterial peptide and method of treatment using the antibacterial peptide

    UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10517953

    Modulators of PCSK9 expression

    Ionis Pharmaceuticals, Inc. · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10518002

    Intraocular drug delivery and filter device and methods of using same

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10519139

    Polymorphs of Selinexor

    Karyopharm Therapeutics Inc. · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10519133

    Vinyl compounds as FGFR and VEGFR inhibitors

    Medshine Discovery Inc. · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10519110

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10519188

    Cyclic di-nucleotide compounds and methods of use

    The Board of Regents of the University of Texas System · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10519205

    Compositions and methods for use of anion channel rhodopsins

    The Board of Regents of the University of Texas System · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10519191

    Bile acid analogs as FXR/TGR5 agonists and methods of use thereof

    Enanta Pharmaceuticals, Inc. · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10519222

    Broadly neutralizing monoclonal antibodies against HIV-1 V1V2 Env region

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10519175

    Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

    COMPASS Pathways Limited · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10519186

    Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus

    Atea Pharmaceuticals, Inc. · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10519224

    Treating headache comprising administering an antibody to calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10519423

    High efficiency reprogramming of fibroblasts into cardiomyocytes

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10519447

    Therapeutic UNA oligomers and uses thereof

    ARCTURUS THERAPEUTICS, INC. · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10519240

    Anti-FGFR1c antibody-FGF21 fusion proteins

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10519247

    Targeting HER2 and HER3 with bispecific antibodies in cancerous cells

    The Board of Regents of the University of Texas System · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2039?

1,782 published patents in our USPTO index have expiration dates falling in calendar year 2039.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.